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Abstract
Background: Fallopian tube involvement by cervical carcinoma has rarely been documented, with literature reports
focusing primarily on squamous cell carcinoma.
Case presentation: In this report, we present the case of a 50 year old woman who presented with an abnormal
Pap test with atypical squamous and glandular cells. A loop electrosurgical excision procedure (LEEP) was
performed and led to the diagnosis of stage IB1 endocervical adenocarcinoma. Subsequent radical hysterectomy,
bilateral salpingo-oophorectomy, and bilateral pelvic lymph node dissection showed a well-differentiated endocervical
adenocarcinoma of usual type with superficial spread to the endometrium and right fallopian tube. The patient
received no adjuvant therapy and has remained without evidence of disease.
Conclusions: While the advent of more extensive fallopian tube sampling has led to increased discovery and
discussion of fallopian tube involvement by metastatic carcinoma, its impact on treatment and prognosis remains
to be seen.
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Background
Because fallopian tube carcinoma was thought to be a
rare occurrence, the fallopian tube had not been empha-
sized in gynecologic malignances until rather recently.
The recognition that serous carcinomas of ovarian type
frequently involved the fallopian tube fimbria [1] has
recently led to the concept that, in fact, the fallopian
tube epithelium was the origin of most high grade ovar-
ian serous carcinomas. There is now a strong interest in
establishing the role of the fallopian tube in gynecologic
malignancies and, increasingly, the entire fallopian tube
is being submitted for histologic analysis.
In this report, we present a case of a 50 year old
woman who was diagnosed with stage IB1 well-
differentiated endocervical adenocarcinoma with surface
extension to the endometrium and fallopian tube, con-
firmed by histologic and immunohistochemical analysis.
Fallopian tube involvement by cervical adenocarcinoma
is a rarely reported entity with as yet unknown effects
on patient outcome. The introduction of more extensive
adnexal sampling may yield similar cases and encourage
further discussion of its significance to treatment and
survival.
Case presentation
A 50 year old woman with a normal Pap smear history
presented in 2012 with an abnormal Pap smear that
showed atypical squamous cells, cannot exclude high
grade lesion (ASC-H) and atypical glandular cells.
Cervical biopsy and endocervical curettage (ECC)
showed atypical glandular/endocervical epithelium. A
loop electrosurgical excision procedure (LEEP) was per-
formed, revealing well-differentiated adenocarcinoma of
the cervix with mucinous and intestinal features. The
tumor measured 12 mm in horizontal spread and
invaded 8 mm into the stroma. The deep stromal, endo-
cervical, and ectocervical margins were positive. PET/
CT was negative for metastatic disease. Given her appar-
ent stage IB1 disease, the patient was dispositioned to
radical hysterectomy, bilateral salpingo-oophorectomy,
and bilateral pelvic lymph node dissection.
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Macroscopically, the cervix revealed a red-tan granular
lesion measuring 3.5 × 3.5 cm. The uterine cavity was
lined with a red-tan, shaggy endometrium measuring up
to 0.4 cm in thickness. The bilateral fallopian tubes and
ovaries appeared grossly normal. Histologically, sections
of the cervix (Fig. 1a) revealed a well-differentiated, neo-
plastic proliferation of glands with focal mucinous and
intestinal differentiation. The lesion invaded 7 mm
where the wall measured 15 mm with surface extension
to the upper genital tract. This included the endomet-
rium and focal non-invasive involvement of the right
fallopian tube (Fig. 1b). No lymphovascular space inva-
sion was identified. The parametria, vaginal cuff mar-
gins, ovaries, and 26 regional lymph nodes were negative
for malignancy. On immunostaining, the tumor cells
from the cervix were diffusely positive for CK7 and p16,
focally positive for mucicarmine, and negative for ER,
CK20, vimentin, CDX2, and p53. An identical staining
pattern was found in sections of the endometrium and
fallopian tube (Fig. 2), supporting extension of the
cervical primary tumor. Formalin-fixed, paraffin-embedded
tissues from the cervix and endometrium were genotyped
using Roche Linear Array® [2]. Both tissues harbored
HPV18 DNA. The morphology and immunostaining pat-
tern supported the diagnosis of invasive adenocarcinoma,
endocervical type with focal mucinous and intestinal differ-
entiation, with involvement of the superficial endometrium
and right fallopian tube. Given the unknown significance
of the tumor in the endometrium and fallopian tube in a
patient with otherwise low-risk disease, no adjuvant
therapy was recommended. She has remained without
evidence of disease since that time (48 mos).
Conclusions
Cervical cancer remains the third most common gyne-
cologic malignancy in the United States, occupying
0.8 % of all new cancer cases in the U.S. [3] Based on
2008–2012 cases and deaths reported in the SEER regis-
try, the number of new cases of cervical cancer was 7.7
per 100,000 women per year [3]. Importantly, the num-
ber of new cases of cervical cancer has been declining
steadily over the past decade, primarily due to improved
Pap smear screening programs. However, this important
trend does not extend to all histologic subtypes of cer-
vical cancer. The rate of squamous cell carcinoma has
declined steadily with the advent of Pap testing, but the
incidence of adenocarcinoma and adenocarcinoma in
situ (AIS) appears to be increasing [4, 5]. Particularly,
adenocarcinoma appears to be occurring at an increased
frequency in younger women [4, 5]. Several factors have
been suggested to explain this trend, including the diffi-
culty in diagnosing glandular lesions via Pap smear and
other etiologic factors such as nulliparity, obesity, and
changes in oral contraceptive use [3].
Upper genital tract involvement by cervical carcinoma
has received little attention, with limited cases reported in
the literature [6, 7]. Ovarian metastasis by cervical cancer is
well recognized; the incidence is reportedly higher in
adenocarcinoma compared to squamous cell carcinoma [8].
The incidence ranges from 2 to 28.6 % in cervical adeno-
carcinoma and 0 to 17.4 % for squamous cell carcinoma,
depending on disease stage [9]. The suggested variable of
tumor size greater than 30 mm affects the incidence of
ovarian metastasis in cervical adenocarcinoma, while ovar-
ian metastasis in cervical squamous cell carcinoma appears
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Fig. 1 Histopathology of cervical adenocarcinoma. a The primary cervical tumor shows well differentiated, mucin depleted glands (Hematoxylin
and eosin, 200x original magnification); b Identical tumor tissue involves the fallopian tube mucosa. There is a sharp demarcation between the
tumor and the normal tubal mucosa. (Hematoxylin and eosin, 200x, original magnification)
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to depend more on clinical stage [8]. Whether due to chan-
ging thoughts about the pathogenesis of ovarian cancer or
other factors, increased fallopian tube sampling has led to
the interesting discovery of metastatic cancers. Rabban et
al. [10] reported the pattern and topography of 100 non-
gynecologic cancers that metastasized to the fallopian
tubes. Most tumors were adenocarcinoma, primarily of
colon and breast origin. The metastatic tumors primar-
ily favored the fimbriae of the fallopian tube, with
patterns of mucosal growth ranging from flat lesions
to lesions with varying degrees of exophytic growth
and stratification [10]. These metastatic tumors can
mimic primary benign and malignant neoplasms of
the fallopian tube, creating a potential diagnostic pit-
fall [10, 11]. In many cases, a high morphologic index
of suspicion along with confirmatory ancillary HPV
testing helped make the correct diagnosis [11].
Compared with ovarian metastasis, reports of cervical
metastasis to the fallopian tube are extremely rare, with
individual case reports primarily of the squamous lesions
[6]. Recently, Reyes et al. [9] analyzed 20 cases of cer-
vical carcinoma with secondary involvement of the uter-
ine corpus and adnexa. Fallopian tube metastasis by
endocervical adenocarcinoma was seen in 8 of 10 cases,
primarily occurring as microscopic lesions [9]. These
microscopic lesions showed mucosal colonization mim-
icking a primary tubal process. To avoid this potential
diagnostic pitfall, the authors emphasized the importance
of analyzing distinct morphologic as well as immunohisto-
chemical features to differentiate between endocervical
adenocarcinoma and primary tubal malignancies.
Histologic evaluation of these metastatic lesions reveal
elongated, hyperchromatic nuclei with focal mucinous
areas and typical histologic features of cervical adeno-
carcinoma, including prominent apical mitoses and nu-
merous apoptotic bodies [9]. Immunohistochemistry and
in-situ hybridization (ISH) can provide further clarifica-
tion of the primary source of malignancy. In particular,
endocervical adenocarcinomas are characterized by posi-
tive HPV ISH and negative p53 overexpression, while
serous tubal intraepithelial carcinomas (STIC) exhibit
p53 overexpression or null pattern and negative HPV ISH.
WT-1 positive immunostaining would also favor a tubal
serous neoplasm [12]. Importantly, immunohistochemis-
try for p16 is not helpful in this differential, as both high-
grade serous tumors and cervical adenocarcinomas are
typically strongly and diffusely positive. Fallopian tube
involvement by metastatic carcinoma, whether gyneco-
logic or non-gynecologic, has received increased attention
with the advent of more extensive fallopian tube sampling.
The current paradigm of high-grade serous carcinomas of
the ovary potentially arising from the fallopian tube may
explain this increased sampling phenomenon [10, 13, 14].
The authors suggest that, due to increased sampling,
recognition of metastatic fallopian tube involvement by
carcinoma may become more frequent.
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Fig. 2 Staining pattern of the tubal metastasis. The higher power image of the tubal lesion, hematoxylin and eosin (400x, original magnification).
Immunohistochemical stains of the tubal tumor show the contrast with the normal tubal tissue. p16 is strongly diffusely positive in the tumor
unlike the normal mucosa (400x, original magnification); p53 shows a wild type pattern similar to the normal mucosa (400x, original magnification);
Estrogen receptor (ER) is negative in the tumor tissue in contrast to the normal (400x, original magnification). This pattern contrasts with the expected
pattern for high grade serous carcinoma arising in the fallopian tube which would typically show positive staining for ER and p53 (mutated)
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In our case, morphologic and immunohistochemical
patterns confirmed the spread of primary cervical
adenocarcinoma to the endometrium and fallopian tube.
The proposed mechanism of upper genital tract involve-
ment by cervical carcinoma is contiguous and transtubal
spread [6]. The effect of fallopian tube involvement on
prognosis and treatment remains unclear. Certainly,
there is concern for possible exposure of the tumor to
the peritoneal cavity. FIGO staging of cervical carcinoma
remains clinical staging and fallopian tube involvement
is not mentioned [15]. The present case suggests that
the spread of endocervical adenocarcinoma to the endo-
metrium and adnexa may not necessarily be associated
with a worse prognosis in patients with disease that is
otherwise localized to the cervix. However, additional
follow-up studies are needed. In conclusion, upper geni-
tal tract involvement by cervical adenocarcinoma re-
mains a rare event, although more extensive adnexal
sampling will likely yield additional examples. The
impact of tubal involvement by cervical cancer on
patient outcome, if any, remains to be established.
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